Memantine and catatonia: A case report and literature review

Journal of Psychiatric Practice

Volumn 17, Issue 4, 2011, Pages 292-299

  Obregon, Demian F ^a   Velasco, Regina M ^a   Wuerz, Timothy P ^a   Catalano, Maria C ^a   Catalano, Glenn ^a   Kahn, David ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

catatonia; geriatric patients; memantine; recurrent major depressive disorder

Indexed keywords

ALENDRONIC ACID; BUSPIRONE; HYDROCHLOROTHIAZIDE; LORAZEPAM; MEMANTINE; MIRTAZAPINE; POTASSIUM CHLORIDE; SERTRALINE; VERAPAMIL;

AGED; BRAIN RADIOGRAPHY; CASE REPORT; CATATONIA; COMPUTER ASSISTED TOMOGRAPHY; EVENING DOSAGE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR DEPRESSION; MINI MENTAL STATE EXAMINATION; MORNING DOSAGE; PASSIVE MOVEMENT; PHYSICAL EXAMINATION; PSYCHOMOTOR RETARDATION; REVIEW; TREATMENT DURATION;

AGED, 80 AND OVER; CATATONIA; DEPRESSIVE DISORDER, MAJOR; DOPAMINE AGENTS; FEMALE; HUMANS; MEMANTINE; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 80051729813     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000400268.60537.5e     Document Type: Review

References (81)

1. Fink M, Taylor MA. Catatonia: A clinicians guide to diagnosis and treatment. Cambridge: Cambridge University Press; 2003.
2. Carroll BT, Thomas C, Jayanti K, et al. Treating persistent catatonia when benzodiazepines fail. Current Psychiatry 2005;4:56-64.
3. Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand 1996;93:129-36. (Pubitemid 26084530)
4. Kahlbaum CL. Klinische Abhandlungen fiber psychische Krankheiten. Berlin: 1874.
5. Bush G, Fink M, Petrides G, et al. Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand 1996;93:137-43. (Pubitemid 26084531)
6. Taylor MA, Fink M. Catatonia in psychiatric classification: A home of its own. Am J Psychiatry 2003;160:1233-41. (Pubitemid 41070938)
7. Kraepelin E. Psychiatrie: Ein Lehrbuch. 8th ed. Leipzig, Germany: J.A. Barth; 1913.
8. Danziger L, Kindwall JA, Lewis HR. Periodic relapsing catatonia: Simplified diagnosis and treatment. Dis Nerv Syst 1948;9:330-5.
9. Gjessing LR. Review of periodic catatonia. Biol Psychiatry 1974;8:23-45.
10. Gjessing R. [Contributions to the somatology of periodic catatonia. Report X. Pathogenetic considerations.]. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr 1960;200:366-89.
11. Minde K. Periodic catatonia, A review with special reference to Rolv Gjessing. Can Psychiatr Assoc J 1966;11: 421-5.
12. Stokes AB. Somatic research in periodic catatonia. J Neurol Psychiatry 1939;2:243-58.
13. Stober G, Ekici A. The periodic catatonia: Evidence for a main gene locus on chromosome 15q15 and first genetic analysis. Nervenarzt 2007;78:62-73.
14. Stober G, Franzek E, Lesch KP, et al. Periodic catatonia- A schizophrenic subtype with major gene effect and anticipation. Eur Arch Psychiatry Clin Neurosci 1995;245: 135-41.
15. Stober G, Seelow D, Ruschendorf F, et al. Periodic catatonia: Confirmation of linkage to chromosome 15 and further evidence for genetic heterogeneity. Hum Genet 2002; 111:323-30. (Pubitemid 36075058)
16. Caroff SN. Catatonia: From psychopathology to neurobiology, 1st edition. Washington, DC: American Psychiatric Publishing; 2004.
17. Anfinson TJ, Cruse J. SIADH associated with catatonia- Its resolution with ECT. Psychosomatics 1995;36:212.
18. Berry N, Sagar R, Tripathi BM. Catatonia and other psychiatric symptoms with vitamin B12 deficiency. Acta Psychiatr Scand 2003;108:156-9.
19. Bhatia MS, Salrabh, Shome S, et al. Recurrent catatonia in Sheehans syndrome (a case report). Indian J Med Sci 1994;48:43-5.
20. Brelinski L, Cottencin O, Guardia D, et al. Catatonia and systemic lupus erythematosus: A clinical study of three cases. Gen Hosp Psychiatry 2009;31:90-2.
21. Catalano G, Catalano MC, Rosenberg EI, et al. Catatonia: Another neuropsychiatric presentation of vitamin B12 deficiency? Psychosomatics 1998;39:456-60. (Pubitemid 28439948)
22. Cooper AF, Schapira K. Case report: Depression, catatonic stupor, and EEG changes in hyperparathyroidism. Psychol Med 1973;3:509-15.
23. Cottencin O, Debien C, Vaiva G, et al. Catatonia and liver transplant. Psychosomatics 2002;43:338-9.
24. Davis EJ, Borde M. Wilsons disease and catatonia. Br J Psychiatry 1993;162:256-9.
25. Dhossche DM, Bouman NH. Catatonia in an adolescent with Prader-Willi syndrome. Ann Clin Psychiatry 1997;9: 247-53. (Pubitemid 28122130)
26. Johnson J. Catatonia: The tension insanity. Br J Psychiatry 1993;162:733-8. (Pubitemid 23168351)
27. Fink M. Treating neuroleptic malignant syndrome as catatonia. J Clin Psychopharm 2001;21:121-2. (Pubitemid 32096768)
28. Hung YY, Yang PS, Huang TL. Clozapine in schizophrenia patients with recurrent catatonia: Report of two cases. Psychiatry Clin Neurosci 2006;60:256-8.
29. Chang CH, Hsiao YL, Hsu CY, et al. Treatment of catatonia with olanzapine: A case report. Prog Neuropsycho - pharmacol Biol Psychiatry 2009;33:1559-60.
30. Dudova I, Hrdlicka M. Successful use of olanzapine in adolescent monozygotic twins with catatonic schizophrenia resistant to electroconvulsive therapy. Neuro Endocrinol Lett 2008;29:47-50.
31. Guzman CS, Myung VHM, Wang YP. Treatment of periodic catatonia with olanzapine: A case report. Rev Bras Psiquiatr 2007;29:380. (Pubitemid 351358066)
32. Guzman CS, Myung VHM, Wang YP. Treatment of periodic catatonia with atypical antipsychotic, olanzapine. Psychiatry Clin Neurosci 2008;62:482.
33. Levy WO, Nunez CY. Use of ziprasidone to treat bipolarassociated catatonia. Bipolar Disord 2004;6:166-7. (Pubitemid 38443572)
34. Cook EH, Jr., Olson K, Pliskin N. Response of organic catatonia to risperidone. Arch Gen Psychiatry 1996;53:82-3. (Pubitemid 26015399)
35. Duggal HS. Risperidone treatment of febrile catatonia in first-episode psychosis. Gen Hosp Psychiatry 2005;27: 80-1. (Pubitemid 40202902)
36. Duggal HS, Gandotra G. Risperidone treatment of periodic catatonia. Can J Psychiatry 2005;50:241-2.
37. Hesslinger B, Walden J, Normann C. Acute and long-term treatment of catatonia with risperidone. Pharmaco - psychiatry 2001;34:25-6. (Pubitemid 32125890)
38. Kopala LC, Caudle C. Acute and longer-term effects of risperidone in a case of first-episode catatonic schizophrenia. J Psychopharmacol 1998;12:314-7. (Pubitemid 28548588)
39. Poyurousky M, Bergman J, Weizman A. Risperidone in the treatment of catatonia in a schizophrenic patient. Isr J Psychiatry Relat Sci 1997;34:323-4.
40. Strawn JR, Delgado SV. Successful treatment of catatonia with aripiprazole in an adolescent with psychosis. J Child Adolesc Psychopharmacol 2007;17:733-5. (Pubitemid 350058979)
41. Nicolato R, Romano-Silva MA, Correa H, et al. Stuporous catatonia in an elderly bipolar patient: Response to olanzapine. Aust N Z J Psychiatry 2006;40:498.
42. Cassidy EM, OBrien M, Osman MF, et al. Lethal catatonia responding to high-dose olanzapine therapy. J Psycho - pharmacol 2001;15:302-4. (Pubitemid 34024250)
43. Mall GD, Hake L, Benjamin AB, et al. Catatonia and mild neuroleptic malignant syndrome after initiation of longacting injectable risperidone: Case report. J Clin Psychopharmacol 2008;28:572-3.
44. Markham-Abedi C, McNeely C, de Leon J. A case report with ziprasidone-induced catatonic symptoms. J Neuro - psychiatry Clin Neurosci 2007;19:476-7. (Pubitemid 350156115)
45. Hanft A, Eggleston CF, Bourgeois JA. Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine. J Child Adolesc Psychopharmacol 2004;14: 481-7. (Pubitemid 39473136)
46. Shepherd J, Garza VM, De Leon OA. Waxing-and-waning catatonia after intermittent exposure to aripiprazole in a case of autism and bipolar disorder. J Clin Psycho - pharmacol 2009;29:503-4.
47. Holtschmidt-Taschner B, Stubner S. Catatonia of neuroleptics syndrome with aripiprazole and paroxetine. Psychopharmakotherapie 2007;14:215-7. (Pubitemid 47605239)
48. Bastiampillai T, Forooziya F, Dhillon R. Clozapine-withdrawal catatonia. Aust N Z J Psychiatry 2009;43:283-4.
49. Biancosino B, Zanchi P, Agostini M, et al. Suspected neuroleptic catatonia induced by clozapine. Can J Psychiatry 2001;46:458. (Pubitemid 32652072)
50. Kalogeropoulou A, Leotsakou C, Fotara I, et al. Catatonia after abrupt discontinuation of chronic clozapine treatment. Eur Psychiatry 2007;22:S120-1.
51. Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophrenia Bull 2010;36:239-42.
52. Goforth H. Amantadine in catatonia due to major depressive disorder in a medically ill patient. J Neuropsychiatry Clin Neurosci 2007;19:480-1. (Pubitemid 350156119)
53. Carpenter SS, Hatchett AD, Fuller MA. Catatonic schizophrenia and the use of memantine. Ann Pharmacother 2006;40:344-6. (Pubitemid 43269871)
54. Munoz C, Yulan N, Achaval V, et al. Memantine in major depression with catatonic features. J Neuropsychiatry Clin Neurosci 2008;20:119-20. (Pubitemid 351295051)
55. Northoff G, Eckert J, Fritze J. Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine. J Neurol Neurosur Psychiatr 1997;62:404-6. (Pubitemid 27199118)
56. Carroll BT, Goforth HW, Thomas C, et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 2007;19:406-12. (Pubitemid 350156098)
57. Prowler ML, Weiss D, Caroff SN. Treatment of catatonia with methylphenidate in an elderly patient with depression. Psychosomatics 2010;51:74-6.
58. Canizares AB, Cano JPJ, Jimenez OG. Clomipramine in the treatment of catatonia. Actas Esp Psiquiatr 1999;27: 273-6.
59. Bialek J, Jarema M. [Treatment of catatonic syndrome with fluoxetine. Case report]. Psychiatr Pol 1999;33:83-9. (Pubitemid 29290863)
60. Coconcea C. Zolpidem in treatment-resistant catatonia: 2 case reports and literature review [abstract]. Schizo - phrenia Res 2008;98:134.
61. Askenazy F, Dor E, Benoit M, et al. Catatonia in a 14 yearold girl: Treatment with clonazepam and carbamazepine, a 10-year follow-up. Encephale 2010;36:46-53.
62. Kritzinger PR, Jordaan GP. Catatonia: An open prospective series with carbamazepine. Int J Neuropsychopharmacol 2001;4:251-7. (Pubitemid 34101521)
63. Yeh YW, Chen CY, Kuo SC, et al. Mirtazapine treatment of periodic catatonia in organic mental disorder: A case report. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:553-4.
64. Di Michele V, Bolino F. A novel treatment option of bipolar depression with psychotic and catatonic features. Gen Hosp Psychiatry 2006;28:364-6.
65. Grisaru N, Chudakov B, Yaroslavsky Y, et al. Catatonia treated with transcranial magnetic stimulation. Am J Psychiatry 1998;155:1608-10. (Pubitemid 28512035)
66. Folstein MF, Folstein SE, McHugh PR. "Mini-mental State": A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res 1975; 12:189-98.
67. Bush G, Fink M, Petrides G, et al. Catatonia I: Rating scale and standardized examination. Acta Psychiatr Scand 1996;93:129-36. (Pubitemid 26084530)
68. Zarate C, Jr, Machado-Vieira R, Henter I, et al. Glutamatergic modulators: The future of treating mood disorders? Harv Rev Psychiatry 2010;18:293-303.
69. Machado-Vieira R, Salvadore G, Ibrahim LA, et al. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des 2009;15:1595-611.
70. Sanacora G. Do glutamatergic agents represent a new class of antidepressant drugs? Part 1. J Clin Psychiatry 2009;70:1473-5.
71. Sanacora G. Do glutamatergic agents represent a new class of antidepressant drugs? Part 2. J Clin Psychiatry 2009;70:1604-5.
72. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793-802.
73. Zarate CA, Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 2006; 63:856-64. (Pubitemid 44188478)
74. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment- resistant major depressive disorder. J Clin Psychiatry 2010;71:1605-11.
75. Mathew SJ, Murrough JW, Aanhet Rot M. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo- controlled continuation trial. Int J Neuropsycho - pharmacol 2010;13:71-82.
76. Zarate CA Jr, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006;163:153-5. (Pubitemid 43050119)
77. Muhonen LH, Lönnqvist J, Juva K, et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008;69:392-9. (Pubitemid 351549391)
78. Kollmar R, Markovic K, Thrauf N, et al. Ketamine followed by memantine for the treatment of major depression. Aust N Z J Psychiatry 2008;42:170.
79. Stewart SE, Jenike EA, Hezel DM, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 2010;30:34-9.
80. Lieberman JA, Papadakis K, Csernansky J, et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuro psychopharmacology 2009;34:1322-9.
81. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-A review of preclinical data. Neuropharma - cology 1999;38:735-67. (Pubitemid 29187336)